Jennifer Hubbard
Nurse Practitioner · Wilmington, DENPI 1962023218
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (40.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Immedica Pharma US, Inc. at 57.2% of the total. Reporting peaked in 2023 at $5,982 and has fallen 85.1% since, to $889 in 2025. Among nurse practitioner clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 137 payments — averaging $84.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Immedica Pharma US, Inc.$7K
- Livanova USA, Inc.$3K
- Jazz Pharmaceuticals Inc.$1K
- UCB, Inc.$398
- Genentech, Inc.$163
- E.r. Squibb & Sons, L.L.C.$105
- plus $377 from 8 others
What the payments were for
- Speaking & faculty fees$3,74032%
- Travel & lodging$3,21228%
- Food & beverage$4,62940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Immedica Pharma US, Inc. | 20 | $6,620 |
| Livanova USA, Inc. | 68 | $2,651 |
| Jazz Pharmaceuticals Inc. | 29 | $1,265 |
| UCB, Inc. | 8 | $398 |
| Genentech, Inc. | 1 | $163 |
| E.r. Squibb & Sons, L.L.C. | 1 | $105 |
| Sumitomo Pharma America, Inc. | 1 | $76 |
| Biocodex, Inc. | 1 | $71 |
| Neurelis, Inc. | 3 | $64 |
| Zogenix Inc. | 1 | $60 |
| SK Life Science, Inc. | 1 | $43 |
| Teva Pharmaceuticals USA, Inc. | 1 | $36 |
| Neos Therapeutics, LP | 1 | $14 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZTALMY$6,320
- VNS Therapy$1,414
- Epidiolex$725
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$359
- OCREVUS$163
- Fintepla$106
- Reblozyl$105
How this compares
$11,580 in reported general payments places this provider in the 95th percentile of 487 nurse practitioner providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EmflazaDeflazacort | 12 | $84,011 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Wilmington
- Colleen DitroWilmington$16K
- Monica SamWilmington$7K
- Brenda NardozziWilmington$7K
- Ellen NeffWilmington$5K
- Tina CubetaWilmington$5K
- Auxilia AkalaWilmington$3K
- Melissa LehrWilmington$3K
- Cathy RamageWilmington$2K
- Meghan McCarterSeaford$170K
- Chandni PatelMiddletown$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.